On February 10, 2020 ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported that several abstracts on ESSA’s lead clinical candidate, EPI-7386, have been selected for presentation at upcoming medical and scientific symposia (Press release, ESSA, FEB 10, 2020, View Source [SID1234554112]). These presentations will provide further preclinical characterization of EPI-7386 including new preclinical data regarding safety studies, gene expression and combination data with antiandrogens.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium
Title: IND Candidate EPI-7386 as an N-terminal Domain Androgen Receptor Inhibitor in Development for the Treatment of Prostate Cancer
Abstract #:
142
Presenter:
Dr. Ronan Le Moigne
Session Title:
Prostate Cancer
Poster Board:
F22
Date:
Thursday, February 13, 2020
Time:
11:30am – 1:00pm PST
Location:
Moscone West Building, San Francisco, CA
American Association for Cancer Research Special Conference on Advances in Prostate Cancer Research
Title: The N-terminal Domain Inhibitor of the Androgen Receptor, EPI-7386, Targets Full Length and Splice Variant Driven Pathways
Presenter:
Dr. Nan Hyung Hong
Poster Session:
B
Date:
Saturday, March 14, 2020
Time:
12:30pm – 3:00pm MST
Location:
Grand Hyatt Denver, Denver, CO
2020 American Urological Association Annual Meeting
Title: The Preclinical Characterization and Development of EPI-7386, an N-terminal domain androgen receptor inhibitor, for the treatment of prostate cancer
Abstract #:
20-6346
Presenter:
Dr. Ronan Le Moigne
Session Title:
Prostate Cancer: Advanced IV
Moderated Poster:
MP79
Date:
Monday, May 18, 2020
Time:
9:30am – 11:30am EST
Location:
Walter E. Washington Convention Center, Washington, D.C.